S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
WARNING: Do You Invest with these Banks (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
WARNING: Do You Invest with these Banks (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
WARNING: Do You Invest with these Banks (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
WARNING: Do You Invest with these Banks (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NYSE:MED

Medifast - MED Stock Forecast, Price & News

$142.87
+4.39 (+3.17%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$137.10
$143.18
50-Day Range
$126.00
$191.56
52-Week Range
$125.18
$239.56
Volume
222,098 shs
Average Volume
141,342 shs
Market Capitalization
$1.57 billion
P/E Ratio
10.60
Dividend Yield
4.74%
Price Target
$214.00

Medifast MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
49.8% Upside
$214.00 Price Target
Short Interest
Healthy
7.89% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.22
Upright™ Environmental Score
News Sentiment
0.50mentions of Medifast in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$556,826 Bought Last Quarter
Proj. Earnings Growth
11.89%
From $11.94 to $13.36 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.15 out of 5 stars

Consumer Staples Sector

4th out of 152 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 5 stocks

MED stock logo

About Medifast (NYSE:MED) Stock

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Medifast from a "buy" rating to a "hold" rating in a research report on Sunday, August 7th. Jefferies Financial Group lowered shares of Medifast from a "buy" rating to a "hold" rating and lowered their price target for the stock from $345.00 to $150.00 in a research report on Thursday, August 4th. Finally, DA Davidson lowered their price target on shares of Medifast from $352.00 to $278.00 and set a "buy" rating on the stock in a research report on Thursday, August 4th.

Medifast Price Performance

Shares of MED Stock opened at $142.87 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.29 and a quick ratio of 0.46. The firm's 50-day moving average is $171.73 and its two-hundred day moving average is $176.97. Medifast has a 12 month low of $125.18 and a 12 month high of $239.56. The company has a market capitalization of $1.57 billion, a PE ratio of 10.60 and a beta of 1.08.

Medifast Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 8th. Shareholders of record on Tuesday, June 28th were paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 4.59%. The ex-dividend date of this dividend was Monday, June 27th. Medifast's dividend payout ratio (DPR) is presently 48.66%.

Insiders Place Their Bets

In other news, Director Jeffrey J. Brown bought 3,940 shares of Medifast stock in a transaction on Tuesday, August 9th. The shares were bought at an average cost of $126.54 per share, with a total value of $498,567.60. Following the completion of the purchase, the director now directly owns 3,940 shares of the company's stock, valued at $498,567.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Jeffrey J. Brown bought 3,940 shares of Medifast stock in a transaction on Tuesday, August 9th. The shares were bought at an average cost of $126.54 per share, with a total value of $498,567.60. Following the completion of the purchase, the director now directly owns 3,940 shares of the company's stock, valued at $498,567.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey J. Brown purchased 399 shares of Medifast stock in a transaction dated Thursday, August 4th. The stock was bought at an average cost of $146.01 per share, for a total transaction of $58,257.99. Following the completion of the purchase, the director now directly owns 35,938 shares in the company, valued at approximately $5,247,307.38. The disclosure for this purchase can be found here. 2.30% of the stock is owned by insiders.

Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

MED Stock News Headlines

Director Of Medifast Makes $498K Buy - Benzinga
Medifast (NYSE:MED) Rating Lowered to Hold at StockNews.com
Medifast (NYSE:MED) Shares Gap Down on Analyst Downgrade
DA Davidson Lowers Medifast (NYSE:MED) Price Target to $278.00
Moderna To $74? Here Are 5 Other Price Target Changes For Thursday
Moderna To $74? Here Are 5 Other Price Target Changes For Thursday
Medifast: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

MED Company Calendar

Last Earnings
11/04/2021
Ex-Dividend for 8/8 Dividend
6/27/2022
Dividend Payable
8/08/2022
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
984
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$214.00
High Stock Price Forecast
$278.00
Low Stock Price Forecast
$150.00
Forecasted Upside/Downside
+49.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$164.03 million
Pretax Margin
12.38%

Debt

Sales & Book Value

Annual Sales
$1.53 billion
Cash Flow
$15.36 per share
Book Value
$17.43 per share

Miscellaneous

Free Float
10,765,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
1.08

Key Executives

  • Mr. Daniel R. Chard (Age 57)
    Exec. Chairman & CEO
    Comp: $3.45M
  • Mr. James P. Maloney CPA (Age 54)
    Chief Financial Officer
    Comp: $1.13M
  • Mr. Anthony E. Tyree (Age 56)
    Chief Marketing Officer
    Comp: $964.79k
  • Mr. Nicholas M. Johnson (Age 42)
    Pres of Coach & Client Experience
    Comp: $1.01M
  • Ms. Lauren Walker (Age 55)
    Exec. VP of Supply Chain Operations
    Comp: $1.07M
  • Mr. Jonathan Barrett MacKenzie (Age 50)
    VP of Fin. & Chief Accounting Officer
  • Mr. Jason L. Groves Esq. (Age 51)
    Exec. VP, Gen. Counsel & Corp. Sec.
  • Ms. Claudia C. Greninger (Age 49)
    Exec. VP of HR













MED Stock - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MED shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price forecast for 2022?

2 Wall Street analysts have issued 12-month price objectives for Medifast's shares. Their MED share price forecasts range from $150.00 to $278.00. On average, they expect the company's share price to reach $214.00 in the next year. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2022?

Medifast's stock was trading at $209.43 on January 1st, 2022. Since then, MED stock has decreased by 31.8% and is now trading at $142.87.
View the best growth stocks for 2022 here
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MED earnings forecast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) announced its quarterly earnings results on Thursday, November, 4th. The specialty retailer reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.92 by $0.64. The specialty retailer earned $413.40 million during the quarter, compared to analysts' expectations of $402.80 million. Medifast had a net margin of 9.44% and a trailing twelve-month return on equity of 87.11%. The company's quarterly revenue was up 52.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.91 earnings per share.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Saturday, June 18th. Stockholders of record on Tuesday, June 28th will be given a dividend of $1.64 per share on Monday, August 8th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 4.59%. The ex-dividend date is Monday, June 27th.
Read our dividend analysis for MED
.

Is Medifast a good dividend stock?

Medifast (NYSE:MED) pays an annual dividend of $6.56 per share and currently has a dividend yield of 4.74%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 48.66%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 49.10% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MED.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of $12.70-$14.10 for the period, compared to the consensus estimate of $15.38. The company issued revenue guidance of $1.58 billion-$1.66 billion, compared to the consensus revenue estimate of $1.81 billion.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.90%), State Street Corp (3.43%), Rice Hall James & Associates LLC (2.74%), Principal Financial Group Inc. (2.20%), Pictet Asset Management SA (1.65%) and Victory Capital Management Inc. (1.12%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $142.87.

How much money does Medifast make?

Medifast (NYSE:MED) has a market capitalization of $1.57 billion and generates $1.53 billion in revenue each year. The specialty retailer earns $164.03 million in net income (profit) each year or $13.48 on an earnings per share basis.

How many employees does Medifast have?

The company employs 984 workers across the globe.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.

This page (NYSE:MED) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.